The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction-Reference-Cited by-同舟云学术

The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction

Published:2019-02 Issue: Volume:208 Page:81-90
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Gibson C. Michael,Kerneis Mathieu,Yee Megan K.,Daaboul Yazan,Korjian Serge,Mehr Ali Poyan,Tricoci Pierluigi,Alexander John H.,Kastelein John J.P.,Mehran Roxana,Bode Christoph,Lewis Basil S.,Mehta Ravindra,Duffy Danielle,Feaster John,Halabi Majdi,Angiolillo Dominick J.,Duerschmied Daniel,Ophuis Ton Oude,Merkely Bela

Funder

CSL Behring

CSL Behring LLC

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference44 articles.

1. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE);Fox;BMJ,2006

2. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective;Jernberg;Eur Heart J,2015

3. Cardiovascular disease risk profiles;Anderson;Am Heart J,1991

4. An updated coronary risk profile. A statement for health professionals;Anderson;Circulation,1991

5. The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non–ST-elevation myocardial infarction;Duffy;Am Heart J,2012

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The mechanisms underlying acute myocardial infarction in chronic kidney disease patients undergoing hemodialysis;Biomedicine & Pharmacotherapy;2024-08

2. Can CSL-112 revolutionize atherosclerosis treatment? A critical look at the evidence;Current Problems in Cardiology;2024-08

3. Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI;Journal of the American College of Cardiology;2024-06

4. CSL112 (Apolipoprotein A‐I [Human]) Reduces the Elevation in Neutrophil‐to‐Lymphocyte Ratio Induced by Acute Myocardial Infarction;Journal of the American Heart Association;2024-05-07

5. High-density lipoprotein infusion therapy: A review;Journal of Clinical Lipidology;2024-05